Recombinant Growth hormone response in Indian girls with Turner syndrome
<p>Turner syndrome (TS) is characterized by short statute and ovarian dysgenesis in females with one X chromosome and partial or complete absence of the second X. It has an estimated birth prevalence of 1/2000 to 1/5000 female live births [1]. There is a global growth delay in TS characterized...
I tiakina i:
Ngā kaituhi matua: | Inderpal Singh Kochar (Author), Smita Ramachandran (Author), Aashish Sethi (Author) |
---|---|
Hōputu: | Pukapuka |
I whakaputaina: |
International Journal of Clinical Endocrinology and Metabolism - Peertechz Publications,
2018-10-29.
|
Ngā marau: | |
Urunga tuihono: | Connect to this object online. |
Ngā Tūtohu: |
Tāpirihia he Tūtohu
Kāore He Tūtohu, Me noho koe te mea tuatahi ki te tūtohu i tēnei pūkete!
|
Ngā tūemi rite
-
Recombinant human growth hormone in the treatment of Turner syndrome
mā: Bessie E Spiliotis
I whakaputaina: (2008) -
Response to three years of growth hormone therapy in girls with Turner syndrome
mā: Hong Kyu Park, me ētahi atu.
I whakaputaina: (2013) -
Concomitant occurrence of Turner syndrome and growth hormone deficiency
mā: Jung Yu, me ētahi atu.
I whakaputaina: (2016) -
Response of children with Turner syndrome with different types of karyotype abnormalities to growth hormone treatment
mā: Jung Eun Choi, me ētahi atu.
I whakaputaina: (2024) -
Apparent mineralocorticoid excess: A case of hypertension in a child with delayed diagnosis leading to stroke
mā: Inderpal Singh Kochar, me ētahi atu.
I whakaputaina: (2019)